Alpha 2.0
Login Register
» Authors » C Twelves

C Twelves

Explore the profile of C Twelves including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 69
Citations 2189
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
J Cassidy
D Lacombe
J Verweij
B Osterwalder
E Van Cutsem
B Reigner
D Allman
W Scheithauer
S B Kaye
S Kaye
Published In
Ann Oncol
Br J Cancer
Eur J Cancer
J Clin Oncol
Cancer Chemother Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Hamilton E, Oliveira M, Turner N, Garcia-Corbacho J, Hernando C, Ciruelos E, et al.
Ann Oncol . 2024 May; 35(8):707-717. PMID: 38729567
Background: SERENA-1 (NCT03616587) is a phase I, multi-part, open-label study of camizestrant in pre- and post-menopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast...
2.
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
Renfro L, Grothey A, Kerr D, Haller D, Andre T, Van Cutsem E, et al.
Ann Oncol . 2015 Feb; 26(5):950-958. PMID: 25697217
Background: Post-treatment survival experience of early colon cancer (CC) patients is well described in the literature, which states that cure is probable for some patients. However, comparisons of treated patients'...
3.
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients
Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M, et al.
Ann Oncol . 2014 Jun; 25(8):1536-43. PMID: 24915873
Background: T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and...
4.
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial
Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, et al.
Br J Cancer . 2014 Feb; 110(6):1438-45. PMID: 24548866
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with...
5.
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Menis J, Twelves C
Breast Cancer (Dove Med Press) . 2013 Dec; 3:101-11. PMID: 24367180
Although metastatic breast cancer remains essentially incurable, many patients previously treated with an anthracycline, taxane, and capecitabine are relatively fit and keen to receive further therapy. Several drugs are used...
6.
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, et al.
Ann Oncol . 2013 Dec; 25(1):132-8. PMID: 24356624
Background: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. Patients And Methods: Patients with stage IIIB/IV disease stratified by adjuvant therapy...
7.
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin
Ploquin A, Olmos D, Lacombe D, AHern R, Duhamel A, Twelves C, et al.
Br J Cancer . 2012 Aug; 107(7):1025-30. PMID: 22910320
Background: Selecting patients with 'sufficient life expectancy' for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ≥ 2 of...
8.
Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
Munro A, Twelves C, Thomas J, Cameron D, Bartlett J
Br J Cancer . 2012 May; 107(1):71-4. PMID: 22644297
Background: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated...
9.
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
Twelves C, Scheithauer W, McKendrick J, Seitz J, Van Hazel G, Wong A, et al.
Ann Oncol . 2011 Sep; 23(5):1190-1197. PMID: 21896539
Background: This multicenter randomized trial compared oral capecitabine with bolus i.v. 5-fluorouracil (5-FU)/folinic acid (FA) as adjuvant therapy for stage III colon cancer. Patients And Methods: Patients were assigned to...
10.
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al.
Ann Oncol . 2011 Mar; 22(12):2604-2609. PMID: 21415237
Background: To compare the effects of oral capecitabine-containing chemotherapy regimens with i.v. 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in patients with gastrointestinal cancers. Methods: A meta-analysis, based on individual...